康莱特注射液对晚期肺癌化疗患者免疫功能的影响 ?

李正国 曾多 席彩霞 陶文学

【摘要】 目的：探讨康莱特注射液对晚期肺癌化疗患者免疫功能的影响。方法：选择2016年8月-2018年6月在笔者所在医院接受化疗的80例肺癌患者的临床资料进行回顾性分析，依据治疗方式不同将其分为对照组和观察组，每组40例。对照组采用常规GP方案化疗，观察组在对照组基础上给予康莱特注射液。比较两组治疗效果。结果：化疗后，两组CD3+、CD4+、CD4+/CD8+水平均较化疗前降低，化疗后观察组的CD3+、CD4+、CD4+/CD8+水平均高于对照组，差异有统计学意义（t=-3.021、-3.511、-6.394，P<0.05）。化疗后，两组CRP、TNF-α、IL-6水平均较化疗前降低，且观察组均低于对照组，差异有统计学意义（t=6.551、21.177、20.139，P<0.05）。观察组不良反应发生率低于对照组，差异有统计学意义（字2=4.528，P<0.05）。结论：对晚期肺癌化疗患者使用康莱特注射液，降低对免疫功能的影响，降低炎性反应程度，安全性良好。

【关键词】 康莱特注射液 晚期肺癌 化疗 免疫功能

[Abstract] Objective： To explore the effect of Kanglaite Injection on immune function in patients with advanced lung cancer undergoing chemotherapy. Method： Clinical data of 80 patients with lung cancer who underwent chemotherapy in our hospital from August 2016 and June 2018 were selected for retrospective analysis. According to different treatment methods， they were divided into the control group and the observation group， with 40 cases in each group. The control group received conventional GP chemotherapy， and the observation group was given Kanglaite Injection on the basis of the control group. The treatment effects of the two groups were compared. Result： After chemotherapy， the levels of CD3+， CD4+， CD4+/CD8+ in both groups were lower than those before chemotherapy， and the levels of CD3+， CD4+， CD4+/CD8+ in the observation group were higher than those in the control group after chemotherapy， the differences were statistically significant （t=-3.021， -3.511， -6.394， P<0.05）. After chemotherapy， the levels of CRP， TNF-α and IL-6 in both groups were lower than those before chemotherapy， and the observation group were lower than those in the control group， the differences were statistically significant （t=6.551， 21.177， 20.139， P<0.05）. The incidence of adverse reactions in the observation group was lower than that in the control group， and the difference was statistically significant （字2=4.528， P<0.05）. Conclusion： The use of Kanglaite Injection in advanced lung cancer patients undergoing chemotherapy can reduce the impact on immune function， reduce the degree of inflammatory response， and is safe.

隨着我国工业化进程速度的不断增加，空气污染程度逐渐加大，再加上人口数量增高，老龄化趋势严重，不良生活习惯和遗传因素等的共同影响，肺癌的人群发病率及死亡率逐年上升[1]。若干研究结果显示，肺癌在诸多癌症之中的发病数量及人群危害最为严重，其所带来的健康损伤也十分惨重[2-3]。针对肺癌的研究一直就是国内外医学界的热点问题。临床上肺癌可以主要分为小细胞肺癌及非小细胞肺癌，其中绝大部分患者罹患的为非小细胞肺癌，该种癌变在早期缺乏特异性的症状，往往出现误诊或漏诊，在确诊时已经进入中晚期，失去最佳的治疗时机[4]。对于部分失去手术机会的肺癌患者而言，目前只能采用化疗的方法延长生存时间，虽然化疗的技术已经出现飞速的进展，但是该种治疗方法的不良反应及对人体造成的损伤，依旧使相当比例的患者无法接受[5-6]。康莱特注射液是近些年出现的一种制剂，该药物从中药薏苡仁提炼，具有调节免疫力及抗癌的功效。本研究选择2016年8月-2018年6月在笔者所在医院接受化疗的80例肺癌患者的临床资料进行回顾性分析，对康莱特注射液对晚期肺癌化疗患者免疫功能的影响进行探讨，现报告如下。